Table 2.
Comparison of adverse events between the STORM and BOSTON trials
| STORM | BOSTON | |||||
|---|---|---|---|---|---|---|
| Selinexor + dexamethasone (n = 123) | Selinexor + bortezomib + dexamethasone (n = 195) | Bortezomib + dexamethasone [n = 204]) | ||||
| Any grade | Grade 3/4 | Any grade | Grade 3/4 | Any grade | Grade 3/4 | |
| Hematologic (%) | ||||||
| Thrombocytopenia | 73 | 58 | 60 | 39.5 | 27.0 | 17.2 |
| Anemia | 67 | 44 | 36.4 | 15.9 | 23.0 | 9.8 |
| Neutropenia | 40 | 21 | 14.9 | 8.7 | 5.9 | 3.4 |
| Non-hematologic (%) | ||||||
| Nausea | 72 | 10 | 50.3 | 7.7 | 9.8 | 0 |
| Fatigue | 73 | 25 | 42.1 | 13.3 | 18.1 | 1.0 |
| Decreased appetite | 56 | 5 | 35.4 | 3.6 | 5.4 | 0 |
| Diarrhea | 46 | 7 | 32.3 | 6.2 | 25.0 | 0.5 |
| Upper respiratory tract infection | 23 | 2 | 29.2 | 3.6 | 21.6 | 1.5 |
| Weight decreased | 50 | 1 | 26.2 | 2.1 | 12.3 | 1.0 |
| Vomiting | 38 | 3 | 20.5 | 4.1 | 4.4 | 0 |
| Cataract | None reported | None reported | 21.5 | 8.7 | 6.4 | 1.5 |
The BOSTON trial data above were presented at ASCO 2020 by Meletios Dimopoulos